Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert outlines the vision for the company's leading anti-cancer drug candidate, AMP945. The biotech is moving to phase two clinical trials for the compound and recently appointed a clinical advisor to oversee the upcoming studies. By creating inhibitors that disrupt the focal adhesion kinase (FAK) protein, Amplia hopes to remove the shield that protects cancerous cells and deliver a deadly blow to diseases like pancreatic cancer.
Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
